Preparations for a surge in demand for dexamethasone are already underway in the wake of Oxford University’s announcement on 16 June that the steroid significantly reduced COVID-19 mortality rates in the university’s ongoing RECOVERY trial.
Regulatory authorities, who have seen demand outstrip supply as publicity outpaced the science, and as waves of COVID-19 infections outpaced...





